Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:CTU OTCMKTS:ENDV OTCMKTS:LENSF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTULe Château Inc. (CTU.V)C$0.01-66.7%C$0.01C$0.01▼C$0.09C$300KN/A114,805 shs719,800 shsENDVEndonovo Therapeutics$0.00+100.0%$0.00$0.00▼$0.00$241K-1.3519.00 million shs3.67 million shsLENSFPresbia$0.02$0.02$0.00▼$0.19$257K5.915,650 shsN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTULe Château Inc. (CTU.V)0.00%0.00%0.00%0.00%0.00%ENDVEndonovo Therapeutics+100.00%-33.33%0.00%-33.33%-81.82%LENSFPresbia0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTULe Château Inc. (CTU.V)N/AN/AN/AN/AN/AN/AN/AN/AENDVEndonovo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALENSFPresbiaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTULe Château Inc. (CTU.V) 0.00N/AN/AN/AENDVEndonovo Therapeutics 0.00N/AN/AN/ALENSFPresbia 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTULe Château Inc. (CTU.V)C$122.47M0.00C$0.04 per share0.27C($3.60) per share0.00ENDVEndonovo Therapeutics$10K24.13N/AN/A($0.08) per share0.00LENSFPresbiaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTULe Château Inc. (CTU.V)N/A-C$2.37N/A∞N/AN/AN/AN/AN/AENDVEndonovo Therapeutics-$2.80MN/A0.00∞N/AN/AN/AN/AN/ALENSFPresbiaN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTULe Château Inc. (CTU.V)N/AN/AN/AN/AN/AENDVEndonovo TherapeuticsN/AN/AN/AN/AN/ALENSFPresbiaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTULe Château Inc. (CTU.V)1,533.650.660.04ENDVEndonovo TherapeuticsN/AN/AN/ALENSFPresbiaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTULe Château Inc. (CTU.V)N/AENDVEndonovo TherapeuticsN/ALENSFPresbiaN/AInsider OwnershipCompanyInsider OwnershipCTULe Château Inc. (CTU.V)N/AENDVEndonovo Therapeutics5.61%LENSFPresbia74.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTULe Château Inc. (CTU.V)N/A29.96 millionN/ANot OptionableENDVEndonovo Therapeutics11.21 billion1.14 billionNot OptionableLENSFPresbia2017.12 millionN/ANot OptionableAFW, CTU, LENSF, and ENDV HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comTop HeadlinesView All Headlines3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI Spending3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeTop Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure Boom3 Top Stocks Under $20 Riding the “Made in America” WaveBy Chris Markoch | July 3, 2025View 3 Top Stocks Under $20 Riding the “Made in America” Wave3 Stocks Poised to Benefit From the "Big Beautiful Bill"By Nathan Reiff | July 7, 2025View 3 Stocks Poised to Benefit From the "Big Beautiful Bill"AFW, CTU, LENSF, and ENDV Company DescriptionsLe Château Inc. (CTU.V) CVE:CTUC$0.01 -0.02 (-66.67%) As of 10/26/2020Le Château Inc. operates as a specialty retailer and manufacturer. It designs, develops, manufactures, and sells fashion apparel, accessories, and footwear for women and men. As of January 25, 2020, the company 129 stores, including 12 fashion outlet stores, as well as an e-commerce platform in Canada. It operates its stores under the Le Château brand. The company was formerly known as Château Stores of Canada Ltd. and changed its name to Le Château Inc. in July 2000. Le Château Inc. was founded in 1959 and is headquartered in Montreal, Canada.Endonovo Therapeutics OTCMKTS:ENDV$0.0002 +0.00 (+100.00%) As of 01:33 PM EasternEndonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.Presbia OTCMKTS:LENSF$0.02 0.00 (0.00%) As of 10/21/2022Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
